NeoGenomics (NASDAQ:NEO) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.

A number of other research firms have also recently weighed in on NEO. Scotiabank set a $22.00 target price on shares of NeoGenomics and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Royal Bank of Canada upped their target price on shares of NeoGenomics from $23.00 to $24.00 and gave the company an “outperform” rating in a research note on Tuesday, March 13th. Zacks Investment Research upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a research report on Friday, February 23rd. BidaskClub upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a research report on Monday, February 5th. Finally, CIBC set a $19.00 price target on shares of NeoGenomics and gave the company a “neutral” rating in a research report on Wednesday, January 3rd. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. NeoGenomics presently has an average rating of “Buy” and a consensus target price of $17.29.

How to Become a New Pot Stock Millionaire

NASDAQ NEO opened at $9.05 on Tuesday. The stock has a market capitalization of $683.51, a P/E ratio of 150.83, a price-to-earnings-growth ratio of 4.72 and a beta of 0.42. NeoGenomics has a twelve month low of $7.08 and a twelve month high of $11.63. The company has a current ratio of 2.42, a quick ratio of 2.21 and a debt-to-equity ratio of 0.56.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Wednesday, February 21st. The medical research company reported $0.04 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.02. The business had revenue of $67.79 million for the quarter, compared to analysts’ expectations of $66.32 million. NeoGenomics had a negative net margin of 1.37% and a positive return on equity of 4.34%. The firm’s revenue for the quarter was up 12.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.05 earnings per share. research analysts anticipate that NeoGenomics will post 0.09 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the business. Fairpointe Capital LLC acquired a new position in shares of NeoGenomics during the fourth quarter worth approximately $2,464,000. Segall Bryant & Hamill LLC lifted its position in shares of NeoGenomics by 16.1% during the fourth quarter. Segall Bryant & Hamill LLC now owns 434,428 shares of the medical research company’s stock worth $3,849,000 after purchasing an additional 60,360 shares in the last quarter. MetLife Investment Advisors LLC acquired a new position in shares of NeoGenomics during the fourth quarter worth approximately $235,000. Stone Ridge Asset Management LLC acquired a new position in shares of NeoGenomics during the fourth quarter worth approximately $281,000. Finally, Guggenheim Capital LLC lifted its position in shares of NeoGenomics by 46.6% during the fourth quarter. Guggenheim Capital LLC now owns 39,457 shares of the medical research company’s stock worth $351,000 after purchasing an additional 12,538 shares in the last quarter. Hedge funds and other institutional investors own 84.63% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “NeoGenomics (NEO) Rating Increased to Buy at ValuEngine” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2018/04/16/neogenomics-neo-rating-increased-to-buy-at-valuengine.html.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.